Bank of America’s Vanda Pharmaceuticals VNDA Stock Holding History

Bank of America’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,500	Closed	-$136K	–	7256
2016 Q4	$136K	Hold	8,500	–	–	﹤0.01%	5490
2016 Q3	$141K	Hold	8,500	–	–	﹤0.01%	5285
2016 Q2	$95K	Buy	+8,500	New	+$82.3K	﹤0.01%	5550
2015 Q2	–	Sell	-55,000	Closed	-$512K	–	7420
2015 Q1	$512K	Buy	+55,000	New	+$621K	﹤0.01%	4304
2014 Q4	–	Sell	-200	Closed	-$2K	–	7994
2014 Q3	$2K	Buy	+200	New	+$2.62K	﹤0.01%	7797
2014 Q2	–	Sell	-42,700	Closed	-$694K	–	8238
2014 Q1	$694K	Buy	42,700 +37,400	+706%	+$532K	﹤0.01%	4275
2013 Q4	$66K	Sell	5,300 -8,600	-62%	-$86.4K	﹤0.01%	6395
2013 Q3	$152K	Buy	13,900 +5,300	+62%	+$56.6K	﹤0.01%	5683
2013 Q2	$69K	Buy	+8,600	New	+$57.9K	﹤0.01%	6375

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's VNDA Position: Q1 2026 in Review

Bank of America increased its Vanda Pharmaceuticals (VNDA) stake by 136% in Q1 2026, buying an estimated $852K and bringing the position to 191,927 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #4356.

Bank of America first reported a position in VNDA in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.4M in Q1 2019. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

Bank of America held 191,927 shares of Vanda Pharmaceuticals worth $1.33M as of Q1 2026.
Bank of America bought 110,513 Vanda Pharmaceuticals shares in Q1 2026, an estimated $852K.
Vanda Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4356 holding.
Bank of America first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Bank of America's Vanda Pharmaceuticals position peaked at $11.4M in Q1 2019.
171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.